Low-dose whole-body angiography for imaging after stroke or TIA
Official title: The Impact of Performing a Low-dose, Whole-body Angiography as the First Element of an Imaging Assessment Following Stroke or Transient Ischemic Attack in Comparison With Usual Care: a Randomized, Controlled, Open Trial
Run by Centre Hospitalier Universitaire de Nīmes · NCT02662751 · Data updated 2026-11-12
This study is testing whether using a low-dose whole-body angiography can help people who have had a stroke or TIA get diagnosed faster and more accurately compared to standard imaging methods.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 89 Years |
| Sex | All |
| Enrollment | 260 (estimated) |
| Sponsor | Centre Hospitalier Universitaire de Nīmes Academic / other |
| Locations | 2 sites (Montpellier and 1 other locations) |
| Status | Recruiting |
| Started | October 21, 2019 |
| Main results expected | June 12, 2026 |
| Study ends | June 12, 2026 |
| Registry record updated | March 10, 2025 |
| Trial ID | NCT02662751 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are patients who have had a stroke or TIA within the past 10 days and meet specific diagnostic criteria.
✕Probably not a fit
Patients who are currently participating in other biomedical research studies or those with certain medical conditions may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study aims to compare two imaging strategies for patients who have experienced a stroke or transient ischemic attack (TIA). One strategy follows the usual imaging protocols at participating centers, while the other begins with a low-dose whole-body angiography. The study will evaluate the number of clinically significant lesions detected, time to diagnosis, hospitalization duration, and overall diagnostic efficiency. Additionally, it will assess the impact on quality of life and the incidence of new cardiovascular events over a follow-up period of 36 months.
Why it matters
Potential benefit: If successful, this approach could lead to faster and more accurate diagnosis and treatment for stroke and TIA patients.
How similar studies have gone: While this approach is innovative, similar studies have shown promise in improving diagnostic efficiency in stroke management.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * The patient was informed about the implementation of the study, its objectives, constraints and patient rights * The patient has given free and informed consent and signed the consent * Patient affiliated with or beneficiary of a health insurance plan * Patient available for 36 months of follow-up * The patient has had a stroke (within the past 10 days, diagnosis confirmed by MRI with a diffusion sequence) or transient ischemic attack (within the past 10 days, ABCD2 score greater than 3) without haemorrhage Exclusion Criteria: * The patient is currently participating in or has participated in another biomedical research study within the past three months or is currently in an exclusion period determined by a previous study. * Patient under guardianship or judicial protection * Refusal to sign the consent * Inability to correctly inform the patient or his/her trusted person about the study * The patient is pregnant, parturient, or breastfeeding * The patient has a contraindication for a treatment used in this study * Known allergy to contrast medium or severe allergy to iodine * Known active malignancy or history of cancer treatment * The patient has already undergone a full body scanner in the previous three months * Renal failure with creatinine clearance below 60 ml / min * Monoclonal immunoglobulin * History of severe symptomatic cardiovascular event (myocardial infarction, aortic dissection, mesenteric ischemia, renal ischemia) * Emergency situations that hamper the planned course of the study
Where it's running
-
CHRU de Montpellier - Hôpital Gui de Chauliac
Montpellier, France Recruiting -
CHRU de Nîmes - Hôpital Universitaire Carémeau
Nîmes, France Not yet recruiting
Study contacts
- Study coordinator: Francesco Macri, MD
- Email: francesco.macri@chu-nimes.fr
- Phone: +33.(0)6.19.42.18.52
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Deep phenotyping to explore recovery in young adults after stroke
This project will test whether a detailed health and sample-collection approach (deep phenotyping) is practical and acceptable for people aged 18–55 who have had a stroke.
-
Stem cell therapy for chronic stroke recovery
This study is testing whether using a patient's own stem cells can help people with long-term stroke recovery feel better and improve their daily functioning.
-
AI-based tools to help diagnose, treat and predict stroke outcomes across multiple hospitals
This study tests AI-powered tools on real-world stroke patients to see if they can improve pre-hospital triage, diagnosis, and outcome prediction while data stay securely within each hospital.
-
Web-based therapy using action observation and mirror therapy for arm weakness after stroke
This trial tests whether a mobile telerehabilitation app delivering action observation therapy (AOT) alone or combined AOT with mirror therapy (AOT-MT) can improve upper limb function in people with subacute stroke.
-
Remote Ischaemic Conditioning for Fatigue After Stroke 2
Aat least 12 weeks after stroke, adults with post-stroke fatigue will try a simple hand-arm cuff treatment at home to see if it helps reduce fatigue.
-
Dual-task balance training plus computer-based cognitive training after stroke
In adults who recently had a stroke, the study tests whether adding computerized cognitive exercises to balance training improves balance and other recovery outcomes.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.